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Colorectal cancer is a major health problem worldwide.
Last year in the United States alone, more than 130 000
people were diagnosed with colorectal cancer and more
than 56 000 died of their disease[1]. Fortunately, this
neoplasm is highly suited to screening because of its long
preclinical phase, during which it is detectable and
curable[2]. Nevertheless, screening programs for colorec-
tal cancer have been only partly successful, owing
largely to poor patient compliance with screening rec-
ommendations[3,4]. A number of organizations including
the World Health Organization (WHO), the American
Cancer Society (ACS), the Agency for Health Care
Policy and Research (AHCPR), the US Preventive
Service Task Force (USPSTF), and the American
Gastroenterology Association (AGA) have issued or
endorsed guidelines for colorectal cancer screening. This
review summarizes the clinical evidence supporting
colorectal cancer screening in the average-risk popula-
tion and in high-risk groups, discusses the advantages
and disadvantages of the available screening tests, and
outlines the currently recommended guidelines for
screening based on risk category.
Average-risk population
Average-risk patients are asymptomatic individuals aged
50 years of age or older who have no personal or family
history of colorectal cancer or adenomatous polyps and
no history of inflammatory bowel disease. The two most
recently published screening recommendations, those of
the ACS[5] and AHCPR[6], present guidelines for screen-
ing average-risk patients in the form of lists of options
(Table 1). The options include annual fecal occult blood
test (not included as a stand alone test in the ACS
guidelines), flexible sigmoidoscopy every 5 years, annual
fecal occult blood test plus flexible sigmoidoscopy every
5 years, double-contrast barium enema every 5 to 10
years, and colonoscopy every 10 years.
Fecal occult blood testing
Fecal occult blood testing (FOBT) is the safest and
least expensive of the currently available screening
tests. Three prospective, randomized, controlled trials
have demonstrated the eﬀectiveness of FOBT in
reducing colorectal cancer mortality by 15% to 33%[7–9].
However, its benefit in reducing colorectal mortality is
attributed not only to early cancer detection but also to
the incidental discovery and removal of adenomatous
polyps at subsequent colonoscopy. Such chance discov-
ery of adenomatous polyps and non-bleeding cancers by
colonoscopy has been estimated to account for 16–25%
of the colorectal cancer deaths prevented by the use of
FOBT[10]. Limitations of FOBT include its relatively
low sensitivity for detecting cancers and its inability to
detect the vast majority of adenomas[11]. Because colo-
rectal cancers bleed intermittently, 50% or more of
patients with colorectal cancer may have a negative
test result[11,12]. Thus, to be eﬀective, FOBT must be
administered annually or biennially, which makes
patient compliance a problem. Furthermore, the positive
predictive value of FOBT is only approximately
10%[11,12].
Table 1 Recommended options for colorectal cancer
screening in asymptomatic, average-risk individuals*
Starting at age 50
Annual FOBT†
Flexible sigmoidoscopy every 5 years
Annual FOBT and sigmoidoscopy every 5 years
Colonoscopy every 10 years
Double-contrast barium enema every 5–10 years
*Winawer SJ, Fletcher RH, Miller L et al. Colorectal cancer
screening: clinical guidelines and rationale. Gastroenterology 1997;
112: 594–642.
†The American Cancer Society does not recommend fecal occult
blood testing (FOBT) by itself.
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Flexible sigmoidoscopy
Data from two case–control studies support the eﬀec-
tiveness of flexible sigmoidoscopy in reducing colorectal
cancer mortality[13,14]. Individuals in these studies who
had undergone at least one screening sigmoidoscopy
during the previous 10 years had only a 21% to 30% risk
of developing fatal colorectal cancer as control subjects.
Compared with colonoscopy, flexible sigmoidoscopy
is less expensive and has a lower complication rate
(approximately one to two perforations per 10 000 ex-
aminations)[6,15]. In addition, it requires a less rigorous
bowel preparation and does not require sedation. The
major disadvantage of flexible sigmoidoscopy, however,
is that it examines only a portion of the colon, thereby
enabling detection of only approximately 50% of colonic
lesions[16,17]. If a polyp is detected by sigmoidoscopy,
colonoscopy is still needed to evaluate the entire colon.
Fecal occult blood testing combined with
flexible sigmoidoscopy
The rationale for combining FOBT with flexible sig-
moidoscopy is two-fold: (1) approximately half of the
cancers missed by FOBT would be detected at sig-
moidoscopy, and (2) FOBT is insensitive for detecting
adenomas, many of which would be detected at sig-
moidoscopy. Nevertheless, there is little direct evidence
to support such a combined approach. Furthermore, a
large number of colonic adenomas and carcinomas are
not within reach of the sigmoidoscope. Although some
of these lesions would be detected when a positive
sigmoidoscopy leads to a follow-up colonoscopy or
barium enema, many of them would be missed, as up to
50% of proximal colonic cancers are not associated with
a distal adenoma[18–22].
Colonoscopy
Colonoscopy is the only colorectal cancer screening test
that allows evaluation of the entire colon and provides
the opportunity to remove polyps and small polypoid
cancers at the same time. Although there are no con-
trolled trials demonstrating that screening colonoscopy
reduces colorectal cancer incidence or mortality in
those at average risk for the disease, indirect evidence
for the eﬀectiveness of colonoscopy comes from one
case–control study[15] and uncontrolled observational
studies[23–25]. The case–control study showed a 40% to
50% reduction in colorectal cancer incidence in individ-
uals who had undergone colonoscopy or polypec-
tomy[15]. A limitation of colonoscopy is that it is
incomplete in 5–15% of patients[18,19,26]. In addition,
colonoscopy is associated with the highest risk of com-
plications of all screening tests. Perforation occurs in
approximately 1 in 1000 colonoscopies, major bleeding
occurs in approximately 3 per 1000, and one to three
patients undergoing colonoscopy die of complications
from the procedure[6,19,26–28].
Barium enema examination
Because of its higher sensitivity than single contrast
barium enema, double-contrast barium enema is consid-
ered the current radiologic alternative to colonoscopy
for colorectal cancer detection. Similar to colonoscopy,
barium enema examination is a test that allows evalu-
ation of the entire colon in approximately 90–95% of
patients[29–31]. No data are available on the sensitivity of
double-contrast barium enema in a screening popula-
tion. In patients undergoing diagnostic examinations,
the reported sensitivity of this test for the detection of
cancer is 85–90%[32–34], and the sensitivity for adenomas
larger than 1 cm is 75–90%[35,36]. However, recently
published data from the National Polyp Study in the
United States demonstrated a sensitivity for double-
contrast barium enema of only approximately 50% for
polyps 1 cm or larger in patients undergoing surveillance
after removal of adenomatous polyps[37]. Advantages
of double-contrast barium enema compared with colon-
oscopy are that it is safer (approximately one perfora-
tion in 25 000 procedures)[38], less expensive, and does
not require sedation. Its major disadvantages are its
lower sensitivity and the inability to remove polyps, thus
requiring colonoscopy or sigmoidoscopy after positive
examinations.
Computed tomography (CT) colonography
CT colonography (also known as ‘virtual colonoscopy’)
is a relatively new radiologic procedure that holds
promise as a colorectal cancer-screening test, but
requires further evaluation. In this study a helically
acquired volumetric data set of the abdomen and pelvis
is obtained after insuﬄation of the colon with air or
carbon dioxide. The colon can then be viewed with
either 2-dimensional or 3-dimensional techniques. The
3-dimensional visualization technique provides a per-
spective that simulates colonoscopic navigation of the
colonic lumen. Prospective studies performed in selected
groups of high-risk patients have reported sensitivities
with CT colonography of 50% to 91% for polyps 1 cm or
larger[39–43]. It is important to note, however, that the
results of such studies cannot be generalized to a screen-
ing population of average-risk individuals. One potential
advantage of CT colonography is the possibility of
avoiding rigorous bowel preparation through the use of
barium stool tagging and electronic subtraction of stool
from the colon prior to diagnostic evaluation of the
images[44]. Whether CT colonography will become a
viable alternative to colonoscopy for colorectal cancer
screening remains to be seen.
Cost-eﬀectiveness
Most studies of the cost-eﬀectiveness of FOBT (every 1
to 2 years), flexible sigmoidoscopy (every 5 years),
colonoscopy (every 10 years) and double-contrast
barium enema examination (every 5 to 10 years) have
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shown costs per life-year saved ranging from approxi-
mately $2000 to $15 000 for FOBT up to $22 000 for
colonoscopy[45–48]. These figures compare favorably with
estimates of cost per life-year saved for breast cancer,
cervical cancer and hypertension screening programs,
which range from approximately $9000 to $50 000[49–50].
Screening recommendations (Table 1)
Recommended options for colorectal cancer screening
of asymptomatic individuals of average risk include the
following (beginning at age 50): annual FOBT (if
positive, examine entire colon with colonoscopy or
double-contrast barium enema examination), flexible
sigmoidoscopy every 5 years (followed by colonoscopy if
adenomatous polyp or cancer found), annual FOBT and
sigmoidoscopy every 5 years, colonoscopy every 10
years, or double-contrast barium enema examination
every 5–10 years. It should be noted that the American
Cancer Society does not endorse the option of FOBT by
itself because of the relatively low mortality reductions
that have been associated with its use[5].
High-risk population
Individuals at increased risk for colorectal cancer are
those with: (1) a personal or family (first degree relative)
history of colorectal cancer or adenoma; (2) longstand-
ing ulcerative or Crohn’s colitis; or (3) a genetic predis-
position to a hereditary polyposis or nonpolyposis
syndrome. Individuals with a single first-degree relative
with colorectal cancer have a risk of developing colo-
rectal cancer approximately 1.7 times that of the general
population[51]. In addition, cancers tend to occur at an
earlier age in this population. First-degree relatives of
patients with adenomas have a similar increased risk
of colorectal cancer[52,53]. Patients with long-standing
ulcerative colitis are at increased risk for colorectal
cancer, particularly those with pancolitis and early age
of onset of their disease[54]. Colorectal cancer in this
group of patients is thought to develop in areas of
mucosal dysplasia. Patients with longstanding Crohn’s
colitis are also at increased risk for colorectal cancer, but
the risk is lower than that associated with ulcerative
colitis[55]. Familial adenomatous polyposis coli (FAP) is
a disease that results from inherited or acquired defects
in the APC gene located on the fifth chromosome.
Patients with this disease develop numerous polyps
throughout the colon, which results in a 100% risk of
colorectal cancer if the colon is not removed. Hereditary
nonpolyposis colorectal cancer (HNPCC) is an auto-
somal dominant disorder that results in a familial pre-
disposition to multiple cancers. The colon cancers
typically occur at a young age, are often located in the
right colon, and may be associated with extracolonic
neoplasms[56].
Screening recommendations (Table 2)
For individuals with first-degree relatives with colo-
rectal cancer or an adenomatous polyp, the screening
recommendations are the same as for the average risk
population, except that screening should begin at age 40.
(Patients with a personal history of colorectal cancer or
adenomatous polyp are not included in this discussion,
as they fall under the category of surveillance rather
than screening.) The recommendation for patients with
FAP is to receive genetic counseling (and possibly
genetic testing to determine if the patient is a gene
carrier) and to undergo flexible sigmoidoscopy annually
beginning at puberty. The recommendation for patients
with HNPCC is to receive genetic counseling (and
possibly genetic testing) and to undergo colonoscopy
every 1–2 years beginning at age 20–30, with annual
colonoscopies beginning at age 40. The recommendation
for patients with longstanding ulcerative colitis is to
undergo colonoscopy with biopsies looking for dysplasia
every 1–2 years beginning 8 years after diagnosis for
pancolitis and beginning 15 years after diagnosis for
left-sided disease. However, there is no direct evidence
that this practice reduces colorectal cancer mortality in
these patients and none that it is more eﬀective than
colectomy based on extent and duration of disease[6].
Surveillance for colorectal cancer is not currently
recommended for patients with Crohn’s colitis[57].
Table 2 Recommendations for colorectal cancer screening in individuals at increased risk*
First-degree relative with colorectal cancer or adenomatous polyp(s): same as for average risk individual, but begin at age 40
Family history of FAP
Genetic counseling (consider genetic testing)
Annual flexible sigmoidoscopy beginning at puberty if gene carrier or indeterminate
Family history of HNPCC
Genetic counseling (consider genetic testing)
Colonoscopy every 1–2 years beginning at age 20–30, annually beginning at age 40
History of inflammatory bowel disease
Consider colonoscopy surveillance for dysplasia every 1–2 years beginning after 8 years of disease for pancolitis and after 15 years of
disease for left-sided colitis
*Winawer SJ, Fletcher RH, Miller L et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112:
594–642.
FAP, familial adenomatous polyposis; HNPCC, hereditary nonpolyposis colorectal cancer.
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Ovarian cancer screening
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Introduction
Ovarian cancer is the most common gynaecological
malignancy in the developed world. It also carries the
worst prognosis with an overall 5-year survival of 30%.
This is likely to be due to the disease frequently present-
ing late, the ovary position within the peritoneal cavity
resulting in minimal local irritation, or interference with
vital structures until ovarian enlargement is consider-
able, or metastasis occurs. Seventy per cent of women
are diagnosed with stage III or IV disease, with 5-year
survivals of 15–20% and less than 5%, respectively[1].
Despite an increase in understanding of the molecular
events underlying malignancy, and advances in both
surgery and chemotherapy, the overall prognosis of
ovarian cancer has changed little over the last 30 years.
However, women who are diagnosed at an early stage do
have a significantly improved prognosis, with survival of
above 80% in stage I disease, and above 90% in those
diagnosed at stage Ia[2]. The best way of improving
outcome may be, therefore, to detect the condition at an
early stage, when the prognosis remains relatively good,
via a screening programme. This is an exciting prospect
and screening trials have shown some encouraging
results. However, as yet screening has not been shown
conclusively to reduce mortality from ovarian cancer. In
addition, our lack of knowledge about disease progres-
sion and of primary peritoneal cancer, as well as the
possible surgical and psychological morbidity that may
result from screening, should be considered. There are
also, of course, cost implications.
What to screen for
A screening programme should ideally be based on the
detection of a pre-malignant condition in order to lower
disease incidence and maximize mortality reduction, as
is the case with the cervical screening programme.
Although it is suggested that inclusion cysts and benign
and borderline ovarian tumours may be pre-malignant,
this remains speculative. Crayford et al. recently ana-
lysed follow-up data from an ovarian cancer screening
trial to assess whether removal of persistent ovarian
cysts was associated with a reduction in mortality from
ovarian cancer[3]. No such reduction was found relative
to other cancers, although it is diﬃcult to interpret the
findings in the absence of a control group, and incidence
may have been a more appropriate end-point than
mortality. In the absence of confirmed pre-malignant
change, screening for ovarian cancer is directed at
present to the detection of pre-clinical disease.
What is required from a screening test
A suitable screening test requires both high sensitivity
and specificity. Women who have a positive screen
require further investigation, often in the form of ex-
ploratory surgery. It is therefore imperative to maximize
specificity in order to obtain a high positive predictive
value, and decrease the number of false-positive screens.
In the general population, a specificity of 99.6% is
required to achieve a positive predictive value of
10%[4], i.e. to limit the number of unnecessary surgical
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